Skip to main content
CGEM
NASDAQ Life Sciences

Cullinan Therapeutics Reports Strong Cash Position and Key Pipeline Milestones, Including Fast Track and NDA Progress

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$11.05
Mkt Cap
$646.294M
52W Low
$5.68
52W High
$13.33
52W Position info
95% above low
Off High info
17% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

CGEM sits 95% above its 52-week low of $5.68.

Summary

Cullinan Therapeutics announced a robust cash position of $439.0 million, providing a runway into 2029, alongside significant pipeline advancements including Fast Track designation for CLN-049 and ongoing NDA submission for zipalertinib.


Key Events · Product Development and Regulatory · CGEM

  • Strong Cash Position and Runway

    Unaudited cash, cash equivalents, short- and long-term investments, and interest receivable were $439.0 million as of December 31, 2025, providing a cash runway into 2029.

  • CLN-049 Receives Fast Track Designation

    CLN-049 received Fast Track designation from the FDA for the treatment of relapsed/refractory acute myeloid leukemia (AML), potentially accelerating its development and review.

  • Zipalertinib NDA Submission Nearing Completion

    Taiho Pharmaceutical Co., Ltd. expects to complete the rolling submission of a New Drug Application (NDA) for zipalertinib in Q1 2026, seeking accelerated approval for EGFR ex20ins NSCLC.

  • Multiple Clinical Data Readouts Expected

    The company plans to share initial data from its CLN-978 studies in rheumatoid arthritis, systemic lupus erythematosus, and Sjögren's disease throughout 2026, alongside updates for Velinotamig and CLN-049.


Analysis · CGEM · Life Sciences

This 8-K filing highlights Cullinan Therapeutics' strong financial health, with a substantial cash position of $439.0 million providing a runway into 2029, which significantly de-risks its operations for several years. The company also reported critical progress across its oncology and immunology pipelines, including a Fast Track designation for CLN-049, which could accelerate its development, and the near completion of a rolling NDA submission for zipalertinib, indicating potential near-term commercialization. Multiple upcoming data readouts for CLN-978 further provide significant catalysts for the stock in 2026.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CGEM was trading at $11.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $646.3M. The 52-week trading range was $5.68 to $13.33. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CGEM - Latest Insights

CGEM
Oct 19, 2026, 7:00 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $13.35
Real-time Price: $11.51 info
Change: -$1.84 (-14%) info
Market Cap: $727.852M info
CGEM
Oct 01, 2026, 7:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.55
Real-time Price: $11.51 info
Change: -$3.04 (-21%) info
Market Cap: $727.852M info
CGEM
Sep 24, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $16.88
Real-time Price: $11.51 info
Change: -$5.37 (-32%) info
Market Cap: $727.852M info
CGEM
Sep 14, 2026, 7:29 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $20.60
Real-time Price: $11.51 info
Change: -$9.09 (-44%) info
Market Cap: $727.852M info
CGEM
Sep 13, 2026, 7:15 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $21.11
Real-time Price: $11.51 info
Change: -$9.60 (-45%) info
Market Cap: $727.852M info